Expert Opinion on Biological Therapy

Article	Citations
Biological therapies for hemophagocytic lymphohistiocytosis: current knowledge and future perspectives	90
Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER – survey)	45
Bispecific antibodies for the treatment of hemophilia A	44
Biologic therapies for chronic obstructive pulmonary disease	43
Bispecific antibodies for immune cell retargeting against cancer	40
The potential for medical therapies to address fistulizing Crohn’s disease: a state-of-the-art review	34
Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial	33
Predisposition to conjunctivitis and male sex reduces drug survival of dupilumab in adults and adolescents	33
Biological therapies for the treatment of psoriasis in pediatrics	31
The history of Crohn’s perianal fistula treatment with mesenchymal stem cells: the story of darvadstrocel	30
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study	29
Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer	29
The ULTIMATE trials: are there advantages of ublituximab over teriflunomide in relapsing multiple sclerosis?	28
Small molecule-regulated switches to provide functional control of CAR T cells within the patient	27
Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies	27
Mosunetuzumab for the treatment of follicular lymphoma	27
Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective	25
Cell-based therapies for the treatment of sports injuries of the upper limb	25
Emerging therapies for human hearing loss	24
Elotuzumab in multiple myeloma	24
Head and neck atopic dermatitis: still a challenging manifestation in the biologic era	24
Safety and pharmacokinetics of a new biosimilar trastuzumab (HL02): a Phase I bioequivalence study in healthy Chinese men	23
Treating psoriasis in the elderly: biologics and small molecules	21
Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group	20
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm cli	20

Evaluation of physicochemical and biological properties of nonreconstituted MYL-1401O vials, reconstituted MYL-1401O suspension in vial, and diluted MYL-1401O suspension in infusion bags (0.9% saline)	20
Analytical similarity assessment of MYL-1402O to reference Bevacizumab	20
A multicenter, randomized, open-label, 2-arm parallel study to compare the pharmacokinetics, safety and tolerability of AVT02 administered subcutaneously via prefilled syringe or autoinjector in healt	19
Clinical updates in mesenchymal stromal cell therapy for osteoarthritis treatment	19
CAR-NK cells: a promising cellular immunotherapy in lymphoma	18
How can clinical safety and efficacy concerns in stem cell therapy for spinal cord injury be overcome?	18
The effect of platelet-rich plasma-fibrin glue dressing in combination with oral vitamin E and C for treatment of non-healing diabetic foot ulcers: a randomized, double-blind, parallel-group, clinical	18
Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease: results of a multicenter survey	18
Fecal microbiota transplantation: a review on current formulations inClostridioides difficileinfection and future outlooks	17
Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study	17
Targeting glyco-immune checkpoints for cancer therapy	16
Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer	16
Biologics in food allergy: up-to-date	15
Targeting the complement system in neuromyelitis optica spectrum disorder	14
HIV-1 cure strategies: why CRISPR?	14
Management of chronic recurrent multifocal osteomyelitis: review and update on the treatment protocol	14
An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas	14
Current and Future Options of Haemophilia A Treatments	14
Current and preclinical treatment options for Merkel cell carcinoma	13
The endosomal-lysosomal system in ADC design and cancer therapy	13
Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males	13
Clinical management and innovation in fracture non-union	13
Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?	12
Could siRNA therapeutics change the way we treat dyslipidemia?	12
Non-traditional approaches for control of antibiotic resistance	12
Switching patterns of biological drugs in patients with psoriasis and psoriatic arthritis: insight from the VALORE database network	12
Antibody drug conjugates for glioblastoma: current progress towards clinical use	12
Next steps for the optimization of exon therapy for Duchenne muscular dystrophy	12
Biosimilars and access to biologic therapy in immune-mediated diseases	12
Industry perspective on regulatory authority (RA) quality reviews of biosimilar applications – an evaluation of RA guidance and expectations for chemical, manufacturing, and controls information throu	12
Novel formats of antibody conjugates: recent advances in payload diversity, conjugation, and linker chemistry	11
Belimumab for the treatment of pediatric patients with lupus nephritis	11
Perceptions of airway gene therapy for cystic fibrosis	11
Addressing high dose AAV toxicity – ‘one and done’ or ‘slower and lower’?	11
Biologic insights from single-cell studies of psoriasis and psoriatic arthritis	11
A comprehensive overview on the anti-inflammatory, antitumor, and ferroptosis functions of bromelain: an emerging cysteine protease	11
The economics of biosimilars and challenges to biosimilar adoption in low- and middle-income countries	11
Therapeutic monoclonal antibodies for COVID-19 management: an update	11
Correction	10
An evaluation of risankizumab for the treatment of moderate-to-severe ulcerative colitis	10
Prospects of cell chemotactic factors in bone and cartilage tissue engineering	10
Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency)	10
Advancements in biologic therapy in eosinophilic asthma	10
Biologics for psoriasis: is there any unmet need left?	10
Muscle invasive bladder cancer: where is the field headed?	10
Assessment of cell-binding capacity of shed rAAV particles after gene therapy vector administration: implications for environmental risk and hygiene recommendations	10
Statement of Retraction	10
Signaling new therapeutic opportunities: cytokines in prostate cancer	10
The role of bDMARDs in the prevention and treatment of inflammatory-related comorbidities in Psoriatic Arthritis	9
Eptinezumab for the treatment of migraine	9

Checkpoint inhibition for early-stage hormone receptor-positive breast cancer	9
Use of rilonacept in patients with recurrent pericarditis during COVID-19 disease	9
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma	9
Global experience of faricimab in clinical settings - a review	9
Interleukin-6 inhibition: a therapeutic strategy for the management of adult-onset Still’s disease	9
Adjuvant immunotherapy for locally advanced renal cell carcinoma	9
Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences	9
Comparison of the efficacy and safety of rapid-acting insulin analogs, lispro versus aspart, in the treatment of diabetes: a systematic review of randomized controlled trials	9
Mechanism of Action of Mesenchymal Stem Cells (MSCs): impact of delivery method	9
Recommendations for pregnancy in Fanconi anemia	9
Long-acting delivery and therapies for neovascular age-related macular degeneration	9
Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors	9
Antibody-based therapeutics for chronic rhinosinusitis with nasal polyps	9
Pooled safety analysis from the VOLTAIRE clinical trials of adalimumab-adbm and adalimumab reference product in patients with rheumatoid arthritis, Crohn’s disease, and chronic plaque psoriasis	9
Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer	9
IL-23 in axial spondyloarthritis and psoriatic arthritis: a good fit for biological treatment?	8
Antibody therapeutics for epithelial ovarian cancer	8
Onasemnogene abeparvovec for the treatment of spinal muscular atrophy	8
Tumor-infiltrating lymphocyte therapy for lung cancer and its future paradigms	8
Cell homing strategy as a promising approach to the vitality of pulp-dentin complexes in endodontic therapy: focus on potential biomaterials	8
The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma	8
Injectable and adhesive hydrogels for dealing with wounds	8
Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma	8
Use of biologics during the COVID-19 pandemic: lessons learned from psoriasis	8
Development of multi-epitope vaccine constructs for non-small cell lung cancer (NSCLC) against USA human leukocyte antigen background: an immunoinformatic approach toward future vaccine designing	8
Survivin as a biological biomarker for diagnosis and therapy	8
Infliximab biosimilar GP1111: a review of 5 years’ post-approval experience	8
Gene Therapy for High Grade Glioma: The Clinical Experience	8
Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer	8
The future of CAR T-cell therapy for B-cell acute lymphoblastic leukemia in pediatrics and adolescents	8
A review of bridging clinical studies between different presentations of biological products approved by the United States Food and Drug Administration (US FDA)	8
Biological therapy in elderly patients with acute myeloid leukemia	8
Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations	7
Recent advances in stem cell therapy for erectile dysfunction: a narrative review	7
Targeting virus-specific CD8+ T cells for treatment of chronic viral hepatitis: from bench to bedside	7
Oncolytic virotherapies for pediatric tumors	7
Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway	7
Epcoritamab in B-cell malignancies: current status and prospects	7
Pathogenesis-oriented therapy of psoriasis using biologics	7
What’s new and what’s next for gene therapy in Pompe disease?	7
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study	7
Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden	7
Intraparenchymal delivery of adeno-associated virus vectors for the gene therapy of neurological diseases	7
Sargramostim in acute radiation syndrome	7
Harmonizing PD-L1 testing in metastatic triple negative breast cancer	7
Total pancreatectomy with intraportal islet autotransplantation for pancreatic malignancies: a literature overview	7
An overview of site-specific methods for achieving antibody drug conjugates with homogenous drug to antibody ratio	7
Does pharmacological intervention prevent or delay the onset of psoriatic arthritis among psoriasis patients?	7
What role can LAG-3-blocking antibodies play in melanoma therapy?	7
Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors	6
The role of antibody therapies in treating relapsed chronic lymphocytic leukemia: a review	6
Optimization of radiation target volume for locally advanced esophageal cancer in the immunotherapy era	6
Experts’ review: the emerging roles of romiplostim in immune thrombocytopenia (ITP)	6
Prostate cancer immunotherapy	6
Overview of biosimilar medicines in Spain: market dynamics, policies, evidence-based insights and avenues for a sustainable market	6
Development and Clinical Translation Considerations for the Next Wave of Gene Modified Hematopoietic Stem and Progenitor Cells Therapies	6
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study	6
Correction	6
Recent developments and industry interest in gene therapy for Duchenne muscular dystrophy	6
Switching CGRP(r) MoAbs in migraine: what evidence?	6
Advances in the optimization of therapeutic drug monitoring using serum, tissue and faecal anti-tumour necrosis factor concentration in patients with inflammatory bowel disease treated with TNF-α anta	6
Current status of mucosal vaccines against SARS-CoV2: a hope for protective immunity	6
What’s new in the use of antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers for cancer therapy?	6
Meta-analysis of response rates to first-line salvage treatment after CAR-T therapy failure in large B-cell lymphoma patients	6
Developing combination therapies with biologics in triple-negative breast cancer	6
Improvement in clinical disease activity index when treatment selection is informed by the tumor necrosis factor-ɑ inhibitor molecular signature response classifier: analysis from the study to acceler	6
Nivolumab + relatlimab for the treatment of unresectable or metastatic melanoma	6
Considerations for the use of biological therapies in elderly patients with rheumatoid arthritis	6
Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions	6
Next-generation CD40 agonists for cancer immunotherapy	6
Antibody-drug conjugates in oncology: insights into Current challenges	6
The global landscape on interchangeability of biosimilars	6
The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target	6
Correction	5
New frontiers in personalized medicine in psoriasis	5
Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis	5
The shifting paradigm of colorectal cancer treatment: a look into emerging cancer stem cell-directed therapeutics to lead the charge toward complete remission	5
IBD goes home: from telemedicine to self-administered advanced therapies	5
Association between cumulative rATG induction doses and kidney graft outcomes and adverse effects in kidney transplant patients: a systematic review and meta-analysis	5
Biologics for dengue prevention: up-to-date	5

An evaluation of mepolizumab as an add-on maintenance treatment for severe eosinophilic asthma	5
Genetic screening in new onset inflammatory bowel disease during anti-interleukin 17 therapy: unmet needs and call for action	5
Stem cell therapy for salivary gland regeneration after radiation injury	5
Ravulizumab for the treatment of myasthenia gravis	5
Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents	5
Bispecific CAR T-cells for B-cell Malignancies	5
Ixekizumab for the treatment of pediatric patients with moderate to severe plaque psoriasis	5
The Role of Anti-IL-1 Treatment in MIS-C Patients	5
Moving toward personalized approaches in the management of lupus nephritis	5
How should we approach salvage therapy in advanced renal cell carcinoma after first-line immunotherapy combinations?	5
Biologic therapy in relapsing polychondritis: navigating between options	5
Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer	5
The evolving therapeutic landscape of diabetic retinopathy	5
The landscape of biosimilars in Saudi Arabia: preparing for the next decade	5
Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces	5
Treatment of migraine with monoclonal antibodies	5
Are monoclonals the way forward to prevent or to treat ventilator-associated pneumonia in the intensive care unit?	5
Biologics in rectal cancer	5
A randomized pharmacokinetic/pharmacodynamic study comparing the bioequivalence of potential biosimilar candidate P044 with reference medicine in healthy volunteers	4
Is sotatercept, which traps activins and growth differentiation factors, a new dawn in treating pulmonary arterial hypertension (PAH)?	4
Near-infrared photoimmunotherapy for the treatment of skin disorders	4
Platelet-rich plasma therapy ensures pain reduction in the management of lateral epicondylitis – a PRISMA-compliant network meta-analysis of randomized controlled trials	4
Need for a risk-based control strategy for managing glycosylation profile for biosimilar products	4
Lisocabtagene Maraleucel for the treatment of B-cell lymphoma	4
Place in therapy of anti-IL-17 and 23 in psoriasis according to the severity of comorbidities: a focus on cardiovascular disease and metabolic syndrome	4
Self-administration of omalizumab: why not? A literature review and expert opinion	4
The evolving role of rituximab in the treatment of pemphigus vulgaris: a comprehensive state-of-the-art review	4
Clinical development of an anti-GPC-1 antibody for the treatment of cancer	4
Pharmacokinetic bioequivalence, safety, and immunogenicity of GB222, a bevacizumab biosimilar candidate, and bevacizumab in Chinese healthy males: a randomized clinical trial	4
Reduced doses of biological therapies in psoriasis: a new potentially “sustainable” frontier of psoriasis treatment	4
Stem cell therapy for acute myocardial infarction: Mesenchymal Stem Cells and induced Pluripotent Stem Cells	4
Is there still a role for talimogene laherparepvec (T-VEC) in advanced melanoma? An indirect efficacy comparison of T-VEC plus ipilimumab combination therapy versus T-VEC alone as salvage therapy in u	4
Immune checkpoint inhibition in COVID-19: risks and benefits	4
Emerging treatment landscape of non-muscle invasive bladder cancer	4
The role of omalizumab in the treatment of chronic rhinosinusitis with nasal polyposis	4
Treatment of fibrous dysplasia: focus on denosumab	4
Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD)	4
A randomized pharmacokinetic-pharmacodynamic evaluation of the potential biosimilar interferon beta-1a product, CinnoVex®	4
Gene therapy for Leber hereditary optic neuropathy	4
What’s new and what’s next for biological and targeted synthetic treatments in psoriatic arthritis?	4
BRAF V600E mutated metastatic colorectal cancer: current progress and future directions	4
Reduction/elimination of blood eosinophils in severe asthma: should there be a safety consideration?	4
Platelet-rich therapies as an emerging platform for regenerative medicine	4
Clinical effectiveness of IL-17 and IL-23 inhibitors on difficult-to-treat psoriasis areas (scalp, genital, and palmoplantar sites): a retrospective, observational, single-center, real-life study	4
Biosimilars: A futuristic fast-to-market advice to developers	4
Hemophilia A gene therapy: current and next-generation approaches	4
Correction	3
An evaluation of mirikizumab for the treatment of ulcerative colitis	3
More failure with solanezumab – this time in preclinical Alzheimer’s disease	3
Examining the impact of biosimilar-to-biosimilar transition on effectiveness and safety	3
Clinical experience of using biosimilars in Crohn’s disease and their effectiveness	3
Physicians’ and patients’ perception of biosimilars and factors affecting biosimilar prescribing in selected Asian countries: a survey study	3
The current status of immunotherapy and future horizon in the treatment of metastatic and locally advanced gastroesophageal adenocarcinoma	3
Emerging role of monoclonal antibodies in the treatment of IgA nephropathy	3
An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer	3
Real-life data of etanercept efficacy and safety in juvenile idiopathic arthritis: a 24-month retrospective study at a single center	3
An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis	3
Correction	3
Rilonacept for the treatment of recurrent pericarditis	3
Biological therapy in polymyalgia rheumatica	3
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature	3
Genetic modification and preconditioning strategies to enhance functionality of mesenchymal stromal cells: a clinical perspective	3
Unmet needs in cervical cancer – can biological therapies plug the gap?	3
IgG-VHH bispecific fusion antibodies: challenges and opportunities as therapeutic agents	3
Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chron	3
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study	3
Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups	3
Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond	3
Bispecific therapeutics: a state-of-the-art review on the combination of immune checkpoint ‎inhibition with costimulatory and non-checkpoint targeted therapy	3
Biologic treatment of psoriasis in oncologic patients	3
Randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of the denosumab biosimilar MW031 in Chinese postmenopausal women with osteoporosis	3
Envafolimab – first PD-1/PD-L1 antibody to be administered by subcutaneous injection for microsatellite instability-high or deficient mismatch repair advanced solid tumors	3
Recent developments in CD19-targeted therapies for follicular lymphoma	3
Relative bioavailability, immunogenicity, and safety of two adalimumab-adbm formulations in healthy volunteers: a double-blind, randomized, single-dose, parallel-arm Phase I trial (VOLTAIRE-HCLF)	3
Oncolytic virus therapy for malignant gliomas: entering the new era	3
Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study	3
An evaluation of exagamglogene autotemcel for the treatment of sickle cell disease and transfusion-dependent beta-thalassaemia	3
Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting	3
Brolucizumab: a novel anti-VEGF humanized single-chain antibody fragment for treating w-AMD	2
Recommendations on TNFα inhibitor biosimilar use in clinical practice: a comparison of European gastroenterology IBD guidance	2
Cardiometabolic comorbidity in the selection of treatment in spondyloarthritis: one step closer to truly personalized medicine?	2
Ranibizumab for the treatment of diabetic retinopathy	2
Monoclonal antibodies for moderate-to-severe atopic dermatitis: a look at phase III and beyond	2
Dynamics of biosimilar uptake in emerging markets	2
Progress towards the clinical use of antimicrobial peptides: challenges and opportunities	2
Conventional type 1 dendritic cells (cDC1) as cancer therapeutics: challenges and opportunities	2
Combination of immune checkpoint inhibitors and tyrosine kinase inhibitors for the treatment of renal cell carcinoma	2
Romosozumab for the treatment of postmenopausal women at high risk of fracture	2
Monoclonal antibodies for treatment of cold agglutinin disease	2
Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma	2
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year	2
Rationale for combining tyrosine kinase inhibitors and T cell redirecting antibodies to mitigate cytokine release syndrome (CRS)	2
An inflammatory triangle in Sarcoidosis: PPAR-γ, immune microenvironment, and inflammation	2
Biosimilars in chronic inflammatory diseases: facts and remaining questions 5 years after their introduction in Europe	2
Luspatercept for β-thalassemia: beyond red blood cell transfusions	2